Literature DB >> 3063481

Increased cyclosporine blood concentrations due to verapamil administration.

T G Maggio1, D W Bartels.   

Abstract

Cyclosporine is an immunosuppressive agent used to prevent rejection of transplanted organs. Monitoring cyclosporine blood concentrations is important to ensure adequate levels to prevent graft rejection while minimizing the risk of toxicity. A 45-year-old man who received a kidney transplant seven months previously is described. He had been receiving cyclosporine along with azathioprine and prednisone for immunosuppression since the transplant. His cyclosporine blood concentrations and renal function were stable during this time. Due to uncontrolled hypertension, sustained-release (SR) verapamil 240 mg/d was added with no change in cyclosporine levels. However, after increasing the dose of verapamil SR to 360 mg/d a dramatic increase in cyclosporine concentrations occurred. His renal function remained stable during this time. The interaction between cyclosporine and the calcium-channel blocking agents along with a possible nephroprotective effect of the calcium-channel blocking agents when used with cyclosporine are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3063481     DOI: 10.1177/106002808802200914

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  9 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 3.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 4.  Keys to long-term care of the liver transplant recipient.

Authors:  Kymberly D Watt
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-13       Impact factor: 46.802

Review 5.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 6.  The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations.

Authors:  T E Jones
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

Review 7.  Emerging treatments for post-transplantation diabetes mellitus.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

8.  The interaction of the diltiazem with oral and intravenous cyclosporine in rats.

Authors:  Sule Kalkan; Mukaddes Gumustekin; Oguz Aygoren; Yesim Tuncok; Ayse Gelal; Hulya Guven
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

Review 9.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.